WASHINGTON, Feb 11 (Reuters) - The U.S. Department of Commerce on Wednesday announced a $252 million settlement with Applied Materials (AMAT.O), opens new tab for illegally exporting chipmaking ...

The AI space is full of booming companies that have the potential to turn meager investments into massive dollar figures. Some are even viewing it as a space that could mint new millionaires. One ...

Artificial intelligence data centers could see $7 trillion in investment by 2030, according to a new McKinsey report. Applied Digital's debt has exploded as it attempts to capitalize on the enormous ...

Applied Digital's strong revenue pipeline and the new data center campus could help it exceed Wall Street's growth expectations. The stock is expensive right now, but it can justify its valuation ...

Applied Digital Corporation (NASDAQ:APLD) is one of the stocks Jim Cramer talked about, along with market froth. Cramer mentioned the stock during the episode and said: Next, there’s a whole new class ...

Dr. Shech is a professor of philosophy who specializes in the philosophy of science. As popular mistrust of expert opinion grows, we increasingly encounter the following skeptical argument about ...

Applied Digital Corporation is moving from a mixed and hard-to-value structure into two focused businesses with clearer roles, funding paths and investor bases. The cloud separation creates a pure AI ...

Applied Digital Corp (NASDAQ:APLD) announced plans to spin off its cloud business, combining with Ekso Bionics (EKSO) to create "ChronoScale." Shares of Applied Digital have pulled back from their ...

From “experimental archaeology” to the mysterious appeal of exploration, the wide-ranging subjects detailed in these titles captivated Smithsonian magazine’s science contributors this year Joe Spring, ...

Kid lit experts weigh in on some of the year’s best science titles. Plus, what to look for when choosing a book for the child in your life. Are you hoping to inspire a young reader in your life with ...

Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics is laying off almost half of the biotech's workforce to conserve its ...

Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question whether the biotech will ever be able to get the drug to market. The New ...